Atypical teratoid/rhabdoid tumour
Updates to Article Attributes
Atypical teratoid/rhabdoid tumours (AT/RT) are uncommon WHO grade 4 tumours, which in the vast majority of cases occurs in young children less than two years of age. It most frequently presents as a posterior fossa mass. AT/RT often resembles medulloblastoma by imaging and even H&E microscopy, and the diagnosis requires cytogenetic analysis of the tissue.
Epidemiology
AT/RTs typically present in very young children (median age is less than 2-3 years 2,13).
Pathology
Microscopic features
Rhabdoid cells are the hallmark of AT/RT, but only comprise a fraction of the tumour and are not required for the diagnosis provided genetic of DNA-methylation changes are compatible (see below) 13.
Other portions of the tumour are indistinguishable on imaging and histology from a medulloblastoma or embryonal tumour with multilayered rosettes.
Genetics
The vast majority (~95%) of AT/RTs have inactivation of both copies of SMARCB1 (also known as INI1, BAF47 or hSNF5). In a small minority of cases (< 5%) it is SMARCA4 (also known as BRG1) that is inactivated 13.
Additionally, AT/RTs can be divided into three subgroups according to DNA-methylation profiling: AT/RT-SHH, AT/RT-TYR, and AT/RT-MYC 13.
To make the diagnosis, either SMARCB1 or SMARCA4 mutations or compatible DNA-methylation profiling need to identified 13.
Immunophenotype
Rhabdoid cells usually demonstrate:
Radiographic features
Atypical teratoid/rhabdoid tumours are usually large and very heterogeneous masses. They may be difficult to distinguish from an embryonal tumour with multilayered rosettes by imaging.
Location
- infratentorial: ~50%
- cerebellum (most common)
- brainstem
- supratentorial
- cerebral hemispheres
- pineal gland region (see pineal mass differential diagnosis)
- septum pellucidum
- hypothalamus
CT
- often isodense to grey matter
- may demonstrate heterogeneous enhancement
- calcification is common
- may show associated obstructive hydrocephalus
MRI
Can show necrosis, multiple foci of cyst formation and sometimes haemorrhage:
- T1: iso- to slightly hyperintense to grey matter (haemorrhagic areas can be more hyperintense)
- T2: generally hyperintense (haemorrhagic areas can be hypointense)
- T1 C+ (Gd): heterogeneous enhancement
- MR spectroscopy
-
DWI
- almost all restrict diffusion
Leptomeningeal seeding has been described in up to 15-30% of cases and so post-contrast imaging of the entire neuroaxis should be considered in suspected AT/RTs.
Treatment and prognosis
Surgery with debulking can be offered in some cases. Tumours can demonstrate leptomeningeal dissemination. Clinically AT/RTs have a much poorer prognosis than medulloblastomas, with little if any response to chemotherapy and death usually occurring within a year of diagnosis.
History and etymology
Primary CNS rhabdoid tumour was first identified as a unique entity in the mid/late 1980s. Prior to this, these tumours were likely misdiagnosed as primitive neuroectodermal tumour/medulloblastoma, as they are relatively similar in microscopic appearance 12. Early reports variably used the term malignant rhabdoid tumour.
Differential diagnosis
Imaging differential considerations include:
- embryonal tumour with multilayered rosettes particularly for supratentorial AT/RTs
-
medulloblastoma
- tends to occur in an older age group 6
- rarely involve cerebellopontine angle
- haemorrhage is much less frequently seen than in AT/RTs 6
- intracranial teratoma
-<p><strong>Atypical teratoid/rhabdoid tumours</strong> <strong>(AT/RT)</strong> are uncommon <a href="/articles/who-classification-of-cns-tumours-1">WHO grade 4</a> tumours, which in the vast majority of cases occurs in young children less than two years of age. It most frequently presents as a <a href="/articles/posterior-fossa-tumours">posterior fossa mass</a>. AT/RT often resembles <a href="/articles/medulloblastoma">medulloblastoma</a> by imaging and even H&E microscopy, and the diagnosis requires cytogenetic analysis of the tissue.</p><h4>Epidemiology</h4><p>AT/RTs typically present in very young children (median age is less than 2-3 years <sup>2,13</sup>).</p><h4>Pathology</h4><h5>Microscopic features</h5><p>Rhabdoid cells are the hallmark of AT/RT, but only comprise a fraction of the tumour and are not required for the diagnosis provided genetic of DNA-methylation changes are compatible (see below) <sup>13</sup>.</p><p>Other portions of the tumour are indistinguishable on imaging and histology from a medulloblastoma or <a href="/articles/embryonal-tumour-with-multilayered-rosettes">embryonal tumour with multilayered rosettes</a>.</p><h5>Genetics</h5><p>The vast majority (~95%) of AT/RTs have inactivation of both copies of SMARCB1 (also known as INI1, BAF47 or hSNF5). In a small minority of cases (< 5%) it is SMARCA4 (also known as BRG1) that is inactivated <sup>13</sup>. </p><p>Additionally, AT/RTs can be divided into three subgroups according to <a href="/articles/dna-methylation">DNA-methylation profiling</a>: AT/RT-SHH, AT/RT-TYR, and AT/RT-MYC <sup>13</sup>.</p><p>To make the diagnosis, either SMARCB1 or SMARCA4 mutations or compatible DNA-methylation profiling need to identified <sup>13</sup>. </p><h5>Immunophenotype</h5><p>Rhabdoid cells usually demonstrate:</p><ul>-<li>-<a href="/articles/epithelial-membrane-antigen-ema">EMA</a>: positive</li>-<li>-<a href="/articles/vimentin">vimentin</a>: positive</li>-<li>-<a href="/articles/smooth-muscle-actin">SMA</a> (smooth muscle actin): positive</li>-</ul><h4>Radiographic features</h4><p>Atypical teratoid/rhabdoid tumours are usually large and very heterogeneous masses. They may be difficult to distinguish from an embryonal tumour with multilayered rosettes by imaging.</p><h5>Location</h5><ul>-<li>infratentorial: ~50%<ul>-<li>cerebellum (most common)</li>-<li>brainstem</li>-</ul>-</li>-<li>supratentorial<ul>-<li>cerebral hemispheres</li>-<li>pineal gland region (see <a href="/articles/pineal-region-mass">pineal mass differential diagnosis</a>)</li>-<li>septum pellucidum</li>-<li>hypothalamus</li>-</ul>-</li>-</ul><h5>CT</h5><ul>-<li>often isodense to grey matter</li>-<li>may demonstrate heterogeneous enhancement</li>-<li>calcification is common</li>-<li>may show associated <a href="/articles/obstructive-hydrocephalus">obstructive hydrocephalus</a>-</li>-</ul><h5>MRI</h5><p>Can show necrosis, multiple foci of cyst formation and sometimes haemorrhage:</p><ul>-<li>-<strong>T1:</strong> iso- to slightly hyperintense to grey matter (haemorrhagic areas can be more hyperintense)</li>-<li>-<strong>T2:</strong> generally hyperintense (haemorrhagic areas can be hypointense)</li>-<li>-<strong>T1 C+ (Gd):</strong> heterogeneous enhancement</li>-<li>-<strong>MR spectroscopy</strong><ul>-<li>-<a href="/articles/choline-peak">Cho</a>: elevated</li>-<li>-<a href="/articles/n-acetylaspartate-naa-peak">NAA</a>: decreased</li>-</ul>-</li>-<li>-<strong>DWI</strong><ul><li>almost all restrict diffusion</li></ul>-</li>-</ul><p>Leptomeningeal seeding has been described in up to 15-30% of cases and so post-contrast imaging of the entire neuroaxis should be considered in suspected AT/RTs.</p><h4>Treatment and prognosis</h4><p>Surgery with debulking can be offered in some cases. Tumours can demonstrate leptomeningeal dissemination. Clinically AT/RTs have a much poorer prognosis than medulloblastomas, with little if any response to chemotherapy and death usually occurring within a year of diagnosis. </p><h4>History and etymology</h4><p>Primary CNS rhabdoid tumour was first identified as a unique entity in the mid/late 1980s. Prior to this, these tumours were likely misdiagnosed as primitive neuroectodermal tumour/<a href="/articles/medulloblastoma">medulloblastoma</a>, as they are relatively similar in microscopic appearance <sup>12</sup>. Early reports variably used the term <strong>malignant rhabdoid tumour</strong>.</p><h4>Differential diagnosis</h4><p>Imaging differential considerations include:</p><ul>-<li>-<a title="Embryonal tumour with multilayered rosettes" href="/articles/embryonal-tumour-with-multilayered-rosettes">embryonal tumour with multilayered rosettes</a> particularly for supratentorial AT/RTs</li>-<li>-<a href="/articles/medulloblastoma">medulloblastoma</a><ul>-<li>tends to occur in an older age group <sup>6</sup>-</li>-<li>rarely involve cerebellopontine angle</li>-<li>haemorrhage is much less frequently seen than in AT/RTs <sup>6</sup>-</li>-</ul>-</li>-<li><a href="/articles/intracranial-teratoma">intracranial teratoma</a></li>- +<p><strong>Atypical teratoid/rhabdoid tumours</strong> <strong>(AT/RT)</strong> are uncommon <a href="/articles/who-classification-of-cns-tumours-1">WHO grade 4</a> tumours, which in the vast majority of cases occurs in young children less than two years of age. It most frequently presents as a <a href="/articles/posterior-fossa-tumours">posterior fossa mass</a>. AT/RT often resembles <a href="/articles/medulloblastoma">medulloblastoma</a> by imaging and even H&E microscopy, and the diagnosis requires cytogenetic analysis of the tissue.</p><h4>Epidemiology</h4><p>AT/RTs typically present in very young children (median age is less than 2-3 years <sup>2,13</sup>).</p><h4>Pathology</h4><h5>Microscopic features</h5><p>Rhabdoid cells are the hallmark of AT/RT, but only comprise a fraction of the tumour and are not required for the diagnosis provided genetic of DNA-methylation changes are compatible (see below) <sup>13</sup>.</p><p>Other portions of the tumour are indistinguishable on imaging and histology from a medulloblastoma or <a href="/articles/embryonal-tumour-with-multilayered-rosettes">embryonal tumour with multilayered rosettes</a>.</p><h5>Genetics</h5><p>The vast majority (~95%) of AT/RTs have inactivation of both copies of SMARCB1 (also known as INI1, BAF47 or hSNF5). In a small minority of cases (< 5%) it is SMARCA4 (also known as BRG1) that is inactivated <sup>13</sup>. </p><p>Additionally, AT/RTs can be divided into three subgroups according to <a href="/articles/dna-methylation">DNA-methylation profiling</a>: AT/RT-SHH, AT/RT-TYR, and AT/RT-MYC <sup>13</sup>.</p><p>To make the diagnosis, either SMARCB1 or SMARCA4 mutations or compatible DNA-methylation profiling need to identified <sup>13</sup>. </p><h5>Immunophenotype</h5><p>Rhabdoid cells usually demonstrate:</p><ul>
- +<li>
- +<a href="/articles/epithelial-membrane-antigen-ema">EMA</a>: positive</li>
- +<li>
- +<a href="/articles/vimentin">vimentin</a>: positive</li>
- +<li>
- +<a href="/articles/smooth-muscle-actin">SMA</a> (smooth muscle actin): positive</li>
- +</ul><h4>Radiographic features</h4><p>Atypical teratoid/rhabdoid tumours are usually large and very heterogeneous masses. They may be difficult to distinguish from an embryonal tumour with multilayered rosettes by imaging.</p><h5>Location</h5><ul>
- +<li>infratentorial: ~50%<ul>
- +<li>cerebellum (most common)</li>
- +<li>brainstem</li>
- +</ul>
- +</li>
- +<li>supratentorial<ul>
- +<li>cerebral hemispheres</li>
- +<li>pineal gland region (see <a href="/articles/pineal-region-mass">pineal mass differential diagnosis</a>)</li>
- +<li>septum pellucidum</li>
- +<li>hypothalamus</li>
- +</ul>
- +</li>
- +</ul><h5>CT</h5><ul>
- +<li>often isodense to grey matter</li>
- +<li>may demonstrate heterogeneous enhancement</li>
- +<li>calcification is common</li>
- +<li>may show associated <a href="/articles/obstructive-hydrocephalus">obstructive hydrocephalus</a>
- +</li>
- +</ul><h5>MRI</h5><p>Can show necrosis, multiple foci of cyst formation and sometimes haemorrhage:</p><ul>
- +<li>
- +<strong>T1:</strong> iso- to slightly hyperintense to grey matter (haemorrhagic areas can be more hyperintense)</li>
- +<li>
- +<strong>T2:</strong> generally hyperintense (haemorrhagic areas can be hypointense)</li>
- +<li>
- +<strong>T1 C+ (Gd):</strong> heterogeneous enhancement</li>
- +<li>
- +<strong>MR spectroscopy</strong><ul>
- +<li>
- +<a href="/articles/choline-peak">Cho</a>: elevated</li>
- +<li>
- +<a href="/articles/n-acetylaspartate-naa-peak">NAA</a>: decreased</li>
- +</ul>
- +</li>
- +<li>
- +<strong>DWI</strong><ul><li>almost all restrict diffusion</li></ul>
- +</li>
- +</ul><p>Leptomeningeal seeding has been described in up to 15-30% of cases and so post-contrast imaging of the entire neuroaxis should be considered in suspected AT/RTs.</p><h4>Treatment and prognosis</h4><p>Surgery with debulking can be offered in some cases. Tumours can demonstrate leptomeningeal dissemination. Clinically AT/RTs have a much poorer prognosis than medulloblastomas, with little if any response to chemotherapy and death usually occurring within a year of diagnosis. </p><h4>History and etymology</h4><p>Primary CNS rhabdoid tumour was first identified as a unique entity in the mid/late 1980s. Prior to this, these tumours were likely misdiagnosed as primitive neuroectodermal tumour/<a href="/articles/medulloblastoma">medulloblastoma</a>, as they are relatively similar in microscopic appearance <sup>12</sup>. Early reports variably used the term <strong>malignant rhabdoid tumour</strong>.</p><h4>Differential diagnosis</h4><p>Imaging differential considerations include:</p><ul>
- +<li>
- +<a title="Embryonal tumour with multilayered rosettes" href="/articles/embryonal-tumour-with-multilayered-rosettes">embryonal tumour with multilayered rosettes</a> particularly for supratentorial AT/RTs</li>
- +<li>
- +<a href="/articles/medulloblastoma">medulloblastoma</a><ul>
- +<li>tends to occur in an older age group <sup>6</sup>
- +</li>
- +<li>rarely involve cerebellopontine angle</li>
- +<li>haemorrhage is much less frequently seen than in AT/RTs <sup>6</sup>
- +</li>
- +</ul>
- +</li>
- +<li><a href="/articles/intracranial-teratoma">intracranial teratoma</a></li>
References changed:
- 2. Meyers S, Khademian Z, Biegel J, Chuang S, Korones D, Zimmerman R. Primary Intracranial Atypical Teratoid/Rhabdoid Tumors of Infancy and Childhood: MRI Features and Patient Outcomes. AJNR Am J Neuroradiol. 2006;27(5):962-71. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7975730">PMC7975730</a> - <a href="https://www.ncbi.nlm.nih.gov/pubmed/16687525">Pubmed</a>
- 2. Meyers SP, Khademian ZP, Biegel JA et-al. Primary intracranial atypical teratoid/rhabdoid tumors of infancy and childhood: MRI features and patient outcomes. AJNR Am J Neuroradiol. 2006;27 (5): 962-71. <a href="http://www.ajnr.org/cgi/content/full/27/5/962">AJNR Am J Neuroradiol (full text)</a> - <a href="http://www.ncbi.nlm.nih.gov/pubmed/16687525">Pubmed citation</a><div class="ref_v2"></div>